While traditional targeting of HER1 for therapy has not been successful, it is feasible that HER1 binding molecules could be used as vectors to effectively deliver imageable or cytotoxic radioactive payloads differentially to MM cells to potentially improve diagnostic as well as therapeutic outcomes. Here, EGFR is linked to Miyoshi myopathy.